Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.7%.
The iShares Biotechnology ETF (IBB) climbed 1.7%.
In corporate news, Amgen (AMGN) shares gained 3.6% after it said its phase 3 trial of dazodalibep met its primary endpoint, showing statistically significant and clinically meaningful improvement in systemic disease activity at week 48 in adults with Sjogren's disease.